Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/o0, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$

BTC h	ealth Limited	
ABN 45 09 ⁻	1 979 172	
We (t	he entity) give ASX the following	g information.
	1 - All issues ust complete the relevant sections (attack	h sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Ordinary Shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	31,841,127
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully Paid Ordinary Shares

Name of entity

⁺ See chapter 19 for defined terms.

Do the *securities rank equally Yes, shares rank equally with all other 4 in all respects from the +issue issued shares, including for dividends. date with an existing +class of quoted +securities? If the additional +securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment \$0.08 Issue price or consideration 5 For the Acquisition and growth funding of Purpose of the issue 6 (If issued as consideration for the Hospital Infusion Business being the acquisition of assets, clearly acquired from Admedus Limited (AHZ.asx) identify those assets) 6a Is the entity an +eligible entity Yes that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 28/11/2018 6b The date the security holder resolution under rule 7.1A was passed 19,544,479 6c Number of *securities issued without security holder approval under rule 7.1 Number of *securities issued 12,296,648 6d with security holder approval under rule 7.1A

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
c c	Number of *securities issued	Nil	
6f	under an exception in rule 7.2	IVII	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	Issue price is \$0.08 per s 75% of the 15 trading da source of the VWAP calc Services.	y VWAP of \$0.098. The
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Remaining capacity under Nil Remaining capacity under 733,005	
7	⁺ Issue dates	22 May 2019	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.	All	+01
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	Number 162,137,659	+Class Ordinary Shares

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
2,500,000	Unlisted Options
	·

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Unchanged			

Part 2 - Pro rata issue

11	Is security holder approval required?	Not applicable
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
	• •	
19	Closing date for receipt of acceptances or renunciations	

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
		•
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

⁺ See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	
33	⁺ Issue	e date	
		uotation of securities	
34	Type (tick o	of *securities one)	
(a)		⁺ Securities described in Part	1
(b)			d of the escrowed period, partly paid securities that become fully paid, a restriction ends, securities issued on expiry or conversion of convertible
Entitie	es tha	t have ticked box 34(a)	
Addit	ional	securities forming a new	class of securities
Tick to docume		e you are providing the informati	on or
35			securities, the names of the 20 largest holders of the ne number and percentage of additional *securities
36			securities, a distribution schedule of the additional mber of holders in the categories
37		A copy of any trust deed for t	he additional ⁺ securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b) 38 Number of *securities for which ⁺quotation is sought +Class of +securities for which 39 quotation is sought 40 Do the *securities rank equally in all respects from the +issue date with an existing +class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do the extent to which they participate for the dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41	Reason	for	request	for	quotation
	now				

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another *security, clearly identify that other *security)

42 Number and *class of all *securities quoted on ASX (including the *securities in clause 38)

Number	+Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 23/05/2019

(Company secretary)

Print name: Stuart Jones

== == == ==

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	130,296,532			
Add the following:				
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2				
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval				
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period				
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 				
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period				
"A"	130,296,532			

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	19,544,479
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	19,544,479 – Capital raised by Sophisticated and Institutional Investors
Under an exception in rule 7.2	
Under rule 7.1A	
• With security holder approval under rule 7.1 or rule 7.4	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	19,544,479
Step 4: Subtract "C" from ["A" x "l placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	19,544,479
Note: number must be same as shown in Step 2	
Subtract "C"	19,544,479
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	Nil
	[Note: this is the remaining placement capacity under rule 7.1]

⁺ See chapter 19 for defined terms.

Rule 7.1A – Additional placement capacity for eligible entities				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
"A"	130,296,532			
Note: number must be same as shown in Step 1 of Part 1				
Step 2: Calculate 10% of "A"				
"D"	0.10			
	Note: this value cannot be changed			
Multiply "A" by 0.10	13,029,653			
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used				
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	12,296,648 - Capital raised by Sophisticated and Institutional Investors			
Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items	12 206 649			
"E"	12,296,648			

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	13,029,653
Note: number must be same as shown in Step 2	
Subtract "E"	12,296,648
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	733,005
	Note: this is the remaining placement capacity under rule 7.1A